<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lecture 4: GABA & E/I Balance</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <h1>Lecture 4: GABA & E/I Balance</h1>
        <nav>
            <ul>
                <li><a href="index.html">Home</a></li>
                <li><a href="lecture1.html">Lecture 1</a></li>
                <li><a href="lecture2.html">Lecture 2</a></li>
                <li><a href="lecture3.html">Lecture 3</a></li>
                <li><a href="lecture4.html">Lecture 4</a></li>
                <li><a href="lecture5.html">Lecture 5</a></li>
                <li><a href="lecture6.html">Lecture 6</a></li>
            </ul>
        </nav>
    </header>

    <section id="lecture4">
        <h2>Key Concepts</h2>
        <ul>
            <li><strong>Ionotropic vs. Metabotropic GABA Receptors:</strong> GABA-A receptors are ionotropic, mediating fast inhibition via Cl⁻ influx. GABA-B receptors are metabotropic, activating G-proteins to regulate K⁺ and Ca²⁺ channels for slower, sustained inhibition.</li>
                <li><strong>Synaptic vs. Extrasynaptic Receptors:</strong> Synaptic GABA-A receptors mediate phasic inhibition, while extrasynaptic receptors are responsible for tonic inhibition, maintaining neuronal excitability at a baseline level.</li>
                <li><strong>Neuronal Shunting:</strong> A form of inhibition where excitatory currents are neutralized by simultaneous inhibitory inputs, preserving the excitation-inhibition (E/I) balance.</li>
                <li><strong>Developmental Shifts:</strong> Early in development, GABA is excitatory due to high intracellular Cl⁻ levels. This shifts to inhibitory as the KCC2 transporter reduces Cl⁻ concentration in mature neurons.</li>
                <li><strong>Role in LTP/LTD:</strong> GABAergic interneurons regulate synaptic plasticity, influencing long-term potentiation (LTP) and long-term depression (LTD) in adjacent excitatory neurons.</li>
                <li><strong>GABAergic Drugs:</strong> Benzodiazepines enhance GABA-A receptor activity, increasing inhibitory tone. Baclofen, a GABA-B agonist, reduces muscle spasticity by suppressing spinal reflex circuits.</li>
                <li><strong>Astrocytic GABA Recycling:</strong> Astrocytes uptake GABA and recycle it via the GABA-glutamate-glutamine cycle, essential for maintaining neurotransmitter balance.</li>
                <li><strong>Interneurons:</strong> GABAergic interneurons play critical roles in synchronizing neural networks and preventing runaway excitation.</li>
                <li><strong>E/I Imbalances:</strong> Disruptions in GABA signaling contribute to neurological disorders like epilepsy, autism, and schizophrenia.</li>
                <li><strong>GABA Receptor Subunit Diversity:</strong> Different subunit compositions in GABA-A receptors dictate their pharmacological properties and localization.</li>
            </ol>
        </ul>
    </section>

    <footer>
        <p>&copy; 2023 Neuropharm Review</p>
    </footer>
</body>
</html>